白细胞分化抗原44系列及拼接变异体与层黏连蛋白受体对葡萄胎恶变的预测  

Predicting evaluation of CD44 series and LN-R in the malignant transformation of hydatidiform mole

作　　者：易村犍[1] 凌晟荣[1] 李军川[2] 陈庭煊[2] 

机构地区：[1]荆州市第一人民医院妇产科,湖北434000 [2]荆州市第一人民医院病理科,湖北434000

出　　处：《中国生育健康杂志》2005年第1期18-20,28,共4页Chinese Journal of Reproductive Health

摘　　要：目的　探讨白细胞分化抗原 4 4 (CD4 4v5、CD4 4v6、CD4 4 )及拼接变异体与层黏连蛋白受体 (LN R)的表达异常和葡萄胎恶变的关系及在预测葡萄胎恶变的价值。　方法　采用针对 4种产物的单克隆抗体 ,链霉素菌生物素蛋白 过氧化物 (S P)法免疫组织化学染色 ,回顾性分析经随访证实发生恶变的葡萄胎 38例 (恶变组 )和未发生恶变的葡萄胎 5 1例 (非恶变组 )中 4种产物的表达情况。　结果　恶变组中CD4 4v5的表达程度显著低于非恶变组 ,恶变组中CD4 4v6表达程度显著高于非恶变组 ,差异有显著性 (P <0 0 5 )。CD4 4v5和CD4 4v6联合应用时 ,对葡萄胎恶变的预测敏感度为 5 2 6 % ,特异度为 88 2 % ,4种产物联合应用加LN R对葡萄胎恶变的预测敏感度为 15 8% ,特异度为 88 2 %。　结论　CD4 4v5和CD4 4v6的表达异常与葡萄胎恶变密切相关 ,用以预测葡萄胎恶变具有较高的价值。ObjectiveTo evaluate the prediction of CD44 CD44v5,CD44v6 and LN R in the malignant transformation of hydatidiform mole.MethodsRetrospective study of the expression of CD44,CD44v5,CD44v6 and LN R were performed on 38 cases of malignant transforming hydatidiform mole (malignant transforming group,MTG)and 51 cases of non malignant transforming mole (non malignant transforming group,NMTG).Formalin fixed and paraffin embedded histological sections were used for immunohistochemistry and untilizing monoclonal antibodies to CD44,CD44v5,CD44v6 and LN R logistic estimate study were also used to analyze the predicting evaluation of the four products in MTG.ResultsThe expression of CD44v6 was significantly elevated in MTG than that in NMTG(P<0 05),while the expression of CD44v5 was significantly reduced in MTG(P<0 05).Furthermore,the expression of the four products as variance for logistic estimate analysis showed that the predicting sensistvity rate of the combined usage of the four products in TMG was 52 6 %,and the specificity rate was 88 2 %.ConclusionAltered expressions of CD44v5 and CD44v6 are correlated with malignant changes of hydatidiform mole and have high predicting evaluation in the malignant transformation of hydatidiform mole.

关 键 词：白细胞分化抗原44系列 拼接变异体 层黏连蛋白受体 葡萄胎 恶变预测 

分 类 号：R737.33[医药卫生—肿瘤]